Zometa^®

Zometa is indicated for the prevention of SREs* in patients with advanced malignancies involving bone.

*SRE=skeletal-related event—defined as pathological fracture, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.zometa.com »

(For Non U.S. Health Care Professionals Only)